Renaissance Technologies (RenTech)'s CRDL Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 772,837 shares of Cardiol Therapeutics Inc. (CRDL) worth $819,207, representing 0.00% of the portfolio. First purchased in 2021-Q3, this short-term holding has been held for 7 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in CRDL for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 543,031 shares. Largest reduction occurred in Q1 2022, reducing 93,000 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Cardiol Therapeutics (CRDL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cardiol Therapeutics (CRDL) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +543,031 | Add 236.30% | 772,837 | $1.06 |
| Q1 2026 | +229,806 | New Buy | 229,806 | $1.35 |
| Q2 2023 | -10,100 | Sold Out | 0 | $0.00 |
| Q1 2023 | +10,100 | New Buy | 10,100 | $0.00 |
| Q1 2022 | -93,000 | Sold Out | 0 | $0.00 |
| Q4 2021 | -51,900 | Reduce 35.82% | 93,000 | $1.84 |
| Q3 2021 | +144,900 | New Buy | 144,900 | $4.13 |
Renaissance Technologies (RenTech)'s Cardiol Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Cardiol Therapeutics Inc. (CRDL) in Q3 2021, acquiring 144,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Cardiol Therapeutics Inc. (CRDL) for 7 quarters since Q3 2021.
Renaissance Technologies (RenTech)'s largest addition to Cardiol Therapeutics Inc. (CRDL) was in Q2 2026, adding 772,837 shares worth $819,207.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 772,837 shares of Cardiol Therapeutics Inc. (CRDL), valued at approximately $819,207.
As of the Q2 2026 filing, Cardiol Therapeutics Inc. (CRDL) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Cardiol Therapeutics Inc. (CRDL) was 772,837 shares, as reported at the end of Q2 2026.